GUCD1 inhibitors are a class of chemical compounds designed to specifically bind to and inhibit the activity of GUCD1, a protein whose function is associated with various cellular processes. These inhibitors are often characterized by their ability to modulate the biochemical pathways mediated by GUCD1, often targeting its enzymatic or signaling functions. Structurally, GUCD1 inhibitors can belong to various chemical scaffolds, exhibiting diverse molecular architectures. These inhibitors are usually small molecules, which allows for high specificity in their interaction with the target protein. The chemical structures of these inhibitors are commonly optimized to enhance binding affinity, selectivity, and inhibitory potency toward GUCD1, ensuring that they can effectively regulate its function at relatively low concentrations.
The development of GUCD1 inhibitors involves detailed studies of the binding pocket and active sites of the protein to identify key interactions that drive inhibitory activity. Structure-activity relationship (SAR) studies play a significant role in refining these compounds to achieve high selectivity and minimal off-target effects. The physicochemical properties of GUCD1 inhibitors, such as lipophilicity, molecular weight, and solubility, are also crucial for their cellular activity and their ability to engage GUCD1 effectively. While some inhibitors may feature simple aromatic or aliphatic substitutions that enable binding, others may possess more complex heterocyclic frameworks or functional groups designed to enhance their interaction with GUCD1. This class of inhibitors is of interest in biochemical and cell biology research to study and understand the pathways regulated by GUCD1 and its role in various physiological or cellular contexts.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Mycophenolic acid | 24280-93-1 | sc-200110 sc-200110A | 100 mg 500 mg | $68.00 $261.00 | 8 | |
Mycophenolic Acid inhibits inosine monophosphate dehydrogenase, potentially affecting guanine nucleotide synthesis and indirectly impacting GUCD1. | ||||||
Ribavirin | 36791-04-5 | sc-203238 sc-203238A sc-203238B | 10 mg 100 mg 5 g | $62.00 $108.00 $210.00 | 1 | |
Ribavirin, an antiviral drug, can influence guanosine metabolism, which might indirectly affect GUCD1. | ||||||
Allopurinol | 315-30-0 | sc-207272 | 25 g | $128.00 | ||
Allopurinol inhibits xanthine oxidase and can affect purine metabolism, potentially having indirect effects on GUCD1. | ||||||
Febuxostat | 144060-53-7 | sc-207680 | 10 mg | $168.00 | 3 | |
Febuxostat, another xanthine oxidase inhibitor, might indirectly modulate GUCD1 by altering purine metabolism. | ||||||
6-Thioguanine | 154-42-7 | sc-205587 sc-205587A | 250 mg 500 mg | $41.00 $53.00 | 3 | |
6-Thioguanine is a purine analog used in cancer therapy that may have indirect effects on GUCD1 function. | ||||||
6-Mercaptopurine | 50-44-2 | sc-361087 sc-361087A | 50 mg 100 mg | $71.00 $102.00 | ||
6-Mercaptopurine, a purine antimetabolite, could influence pathways associated with GUCD1. | ||||||
Methotrexate | 59-05-2 | sc-3507 sc-3507A | 100 mg 500 mg | $92.00 $209.00 | 33 | |
Methotrexate, an inhibitor of dihydrofolate reductase, can impact purine synthesis, potentially affecting GUCD1. | ||||||
Azathioprine | 446-86-6 | sc-210853D sc-210853 sc-210853A sc-210853B sc-210853C | 500 mg 1 g 2 g 5 g 10 g | $199.00 $173.00 $342.00 $495.00 $690.00 | 1 | |
Azathioprine, a prodrug of 6-mercaptopurine, might indirectly affect GUCD1 through its action on purine metabolism. | ||||||
Tiazofurin | 60084-10-8 | sc-475805 | 5 mg | $440.00 | ||
Tiazofurin inhibits inosine monophosphate dehydrogenase, potentially impacting GUCD1. | ||||||
Clofarabine | 123318-82-1 | sc-278864 sc-278864A | 10 mg 50 mg | $185.00 $781.00 | ||
Clofarabine, a nucleoside analog, can affect nucleotide metabolism and might have indirect effects on GUCD1. | ||||||